Halozyme Therapeutics (HALO) Set to Announce Earnings on Thursday
Halozyme Therapeutics (NASDAQ:HALO) is scheduled to be posting its Q413 quarterly earnings results on Thursday, February 27th. Analysts expect Halozyme Therapeutics to post earnings of ($0.17) per share and revenue of $16.39 million for the quarter.
Halozyme Therapeutics (NASDAQ:HALO) opened at 16.22 on Wednesday. Halozyme Therapeutics has a 52-week low of $5.03 and a 52-week high of $18.18. The stock has a 50-day moving average of $15.61 and a 200-day moving average of $12.51. The company’s market cap is $1.829 billion.
Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Halozyme Therapeutics from $4.00 to $4.50 in a research note on Monday, January 27th. Analysts at Barclays reiterated an “equal weight” rating on shares of Halozyme Therapeutics in a research note on Friday, January 10th. They now have a $15.00 price target on the stock, up previously from $12.00. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Halozyme Therapeutics has a consensus rating of “Hold” and a consensus price target of $11.21.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.